Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Erez Vigodman said today, “If the Mylan Pharmaceuticals shareholders support the acquisition of Perrigo, Teva will abandon its bid for Mylan.” Vigodman made his remarks at a meeting held for its institutional shareholders.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Three Way Takeover Battle: Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced on Friday that it has completed the purchase of a 4.61% More…
Three Way Takeover Battle: Teva’s Mylan Stake Up to 4.3%
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) continues to accumulate shares in takeover target Mylan (MYL), even as Mylan’s largest shareholder, Abbott Labs (NYSE: ABT), announced its More…
Three Way Takeover Battle: Mylan to List on TASE if Perrigo Bid Succeeds
One of the main worries of Tel Aviv Stock Exchange (TASE) leaders recently has been the expected delisting of Perrigo Company (NYSE:PRGO; TASE:PRGO), if and when the company’s acquisition by Mylan More…
Three Way Takeover Battle: Abbott Labs to Back Mylan’s Acquisition of Perrigo
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott Lab potentially helping Mylan forfend $40 More…
Three Way Takeover Battle: Statistics Weigh Against Teva’s Mylan Bid Succeeding
Will drug company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) succeed in its attempted hostile takeover of rival Mylan (MYL), or will it be Mylan that succeeds in its own hostile takeover More…
Teva Issues New Letter to Mylan NV Confirming Seriousness of Offer to Acquire Mylan
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) issued a new open letter on Monday, signed by both the Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, addressed to Robert More…
Mylan to Teva: Stop Playing Games With Our Company
Mylan reports that Teva Pharmaceutical Industries, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake, but did not clarify which anti-trust rule it violated. Five More…
Mylan’s CEO on Teva “They Are Getting Ready to Go Off the Cliff”
“We just don’t think Teva is the right company” to combine with, “They are getting ready to go off the cliff, ” Mylan NV, CEO Heather Bresch said Friday at a conference in New York City hosted by Sanford More…
Perrigo CEO Will Discuss Deal With Mylan at Right Price
Perrigo Company (NYSE:PRGO; TASE:PRGO) CEO Joseph Papa is ready to talk with Mylan N.V. (MYL) about its takeover bid, but at a higher price. The rival drugmaker’s present bid is nowhere near there. Perrigo More…
